Is inflammation the silent culprit behind the two most deadly global diseases—cancer and cardiometabolic disorders?

In this episode of Medicine for Good, Dr. Julieta Gabiola welcomes Felix Oen and Dr. Han Chong Toh to explore the powerful link between chronic inflammation, cancer, and cardiometabolic diseases. Research shows that persistent low-grade inflammation weakens the immune system, increases cancer risk, and fuels conditions like diabetes and heart disease.

The discussion highlights AI’s transformative role in healthcare, enabling early disease detection, precision medicine, and remote monitoring. Dr. Toh and Oen explain how AI-driven tools improve diagnostics and identify high-risk patients before symptoms appear, offering game-changing advancements in patient care.

Another key focus is the epidemic of fatty liver disease, which affects one in three people worldwide and significantly raises risks for cirrhosis, liver cancer, and metabolic disorders. The conversation also explores repurposed medications like aspirin, metformin, and statins in reducing cancer risk.

As the episode concludes, the guests emphasize a holistic approach to healthcare, stressing the importance of AI integration, lifestyle interventions, and early screenings in managing chronic diseases.

About Felix Oen

Felix Oen is a biomedical entrepreneur and co-founder of TikaHealth, a bioinformatics platform designed to enhance personalized healthcare, precision medicine, and patient data management. With a background in integrative medicine, AI, and machine learning, he has led multiple ventures in digital health, focusing on predictive analytics and early disease detection, particularly for cancer and liver diseases. Built during the COVID-19 pandemic, TikaHealth is now utilized by clinicians across cities to improve patient care, health literacy, and accessibility. Beyond his professional career, Felix is deeply involved in community initiatives, supporting marginalized groups and children-at-risk in Singapore and the region. Known for his leadership, strategic planning, and analytical expertise, he is committed to driving innovation in global healthcare.

About Dr. Han Chong Toh

Dr. Han Chong Toh is a distinguished medical oncologist with over 25 years of experience in clinical care and translational cancer research. As the Deputy Chief Executive Officer of the National Cancer Centre Singapore (NCCS), he leads strategic initiatives and the development of innovative cancer therapies. He is also a tenured professor at Duke-NUS Medical School and an Adjunct Principal Investigator at the Singapore Immunology Network and the Institute of Molecular and Cell Biology. His research spans cancer immunology, immunotherapy, inflammation, and health policy, earning him multiple accolades, including the National Senior Clinician Scientist Award. Committed to advancing cancer treatment, he champions academic-industry collaborations, innovation, and impactful healthcare solutions.

About the Host:

Dr. Jette is a Clinical Professor of Medicine at Stanford University and the President & CEO of ABCs for Global Health. Click here for her full profile or read her full interview here.

Hosted on Acast. See acast.com/privacy for more information.